Vertebral Artery Dissection: Antithrombotic Management
For vertebral artery dissection associated with ischemic stroke or TIA, treat with either antiplatelet therapy (aspirin 75-325 mg daily, clopidogrel 75 mg daily, or aspirin plus extended-release dipyridamole 25/200 mg twice daily) OR anticoagulation (heparin/LMWH bridged to warfarin with target INR 2.0-3.0) for 3-6 months 1.
Treatment Selection Algorithm
The 2011 ASA/ACCF/AHA guideline provides Class IIa evidence that both treatment strategies are reasonable, with no clear superiority of one over the other 1. This is strongly supported by the most recent high-quality meta-analysis from 2022, which found no statistically significant differences between antiplatelets and anticoagulants for stroke, stroke/TIA, or death outcomes 2.
Choose Antiplatelet Therapy When:
- Patient has standard posterior circulation stroke/TIA from VAD
- No evidence of intraluminal thrombus on imaging
- Lower bleeding risk preferred
- Patient preference for oral therapy without INR monitoring
Choose Anticoagulation When:
- Angiographic evidence of thrombus at the vertebral artery origin or extracranial portion 1
- Vessel occlusion present (may confer additional benefit) 3
- Concurrent indication exists (atrial fibrillation, mechanical valve) 1
Treatment Duration and Monitoring
- Continue antithrombotic therapy for 3-6 months 1
- Perform follow-up vascular imaging at 3-6 months to assess healing
- If vessel has healed: Discontinue anticoagulation; may continue aspirin 75-100 mg daily if residual stenosis present 4
- If persistent dissection/stenosis: Continue antiplatelet therapy long-term
Critical Evidence Synthesis
The guideline recommendation is based on Class IIa evidence (reasonable to use either approach), acknowledging the absence of randomized trial data specifically for VAD 1. Two recent meta-analyses (2022 and 2021) analyzing pooled observational data and limited RCTs confirm no significant difference in efficacy or major bleeding between the two strategies 2, 5. A 2013 observational study of 110 VAD patients found recurrent ischemic events were rare (1 case) regardless of treatment choice, with no bleeding complications in either group 6.
Common Pitfalls to Avoid
- Do not withhold treatment pending "perfect" imaging: Start antithrombotic therapy promptly once VAD is diagnosed, as early ischemic events occur within the first 2-4 weeks 3
- Do not combine aspirin plus clopidogrel: This increases hemorrhage risk without proven benefit 1
- Do not assume VAD is a contraindication to thrombolysis: In acute presentation with stroke symptoms, intravenous thrombolysis can be considered and has shown safety in case reports 7, 8
- Do not stop surveillance after initial healing: Late contralateral dissection can occur, though rare, even after years of stability 9
Special Considerations
For patients with aspirin allergy or contraindication, clopidogrel 75 mg daily or ticlopidine 250 mg twice daily are reasonable alternatives 1. If anticoagulation is chosen, bridge with heparin or LMWH to therapeutic warfarin (INR 2.0-3.0) 1.
The functional outcome is generally favorable regardless of antithrombotic choice, with most patients achieving modified Rankin Score ≤2 6. Recurrent dissection is uncommon, occurring in <5% of cases 4.